KONEXChemicals233990

Jilgyungyi

₩747▲ 14.92%2026-11-18 close
Market Cap
₩12B
Turnover
₩747
Volume
1 shares
Shares out.
16.1M
PER
—
PBR
—
EPS
—
Dividend Yield
0.00%

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-11-18 close

01

Report overview

Export-Led Profit, Thin Liquidity

Jilgyungyi reshaped its 2025 earnings through exports and online channels, but as a KRW 9.8 billion KONEX stock its trading base remains fragile.

  1. 1

    For fiscal 2025 on a separate basis, revenue was KRW 13,003 million, operating profit KRW 2,515 million and net profit KRW 3,234 million.

  2. 2

    Press reports say export sales rose about 85% in 2025, driven by live commerce with Chinese influencers.

  3. 3

    In April 2026 the company raised about KRW 3 billion through a third-party rights offering to the Daishin-SBI KONEX Scale-up Fund.

  4. 4

    The share price was KRW 606 on October 27, 2026, and trading value was only KRW 94,100.

  5. 5

    The company has set expansion into the US and Indonesia and a 2027 KOSDAQ transfer as its goals.

02

Business structure

Jilgyungyi is an other-chemical-products manufacturer listed on KONEX on December 29, 2015, and it is described as a femtech company. Its business has a cosmetics division that makes and sells feminine hygiene products and a pharmaceutical development arm that handles women's health patents and R&D.

Products include feminine cleansers in tablet, gel, foam and single-use tissue formats, and the company also sells whitening cream and sanitary pads. The pharmaceutical side is at a development stage, running clinical trials on treatments for vaginitis, vaginal laxity and vaginal dryness.

Export sales in 2025 were KRW 5.3 billion versus KRW 2.9 billion a year earlier, up about 85%, driven by live commerce with influential Chinese influencers. In Korea it strengthened direct channels centered on Coupang and its own online mall while cutting the share of lower-margin home shopping.

It agreed to acquire production equipment worth KRW 1.63 billion to meet rising China exports of syringe-type gel. Although classified under chemicals, its business differs from large chemical makers such as LG Chem and Lotte Chemical, so direct comparison is difficult.

The global femtech market is forecast to reach USD 55.88 billion in 2026, with a compound annual growth rate of 20.2%.

03

Recent trends

For fiscal year 13 (2025) on a separate basis, revenue was KRW 13,003 million, operating profit was KRW 2,515 million and net profit was KRW 3,234 million. Consolidated net profit was KRW 3,507 million, and earnings per share were also positive.

Total assets were KRW 14,283 million, total liabilities KRW 7,781 million and total equity KRW 6,502 million. Revenue rose about 30% from KRW 10.0 billion the year before, and operating profit more than doubled from KRW 1.1 billion.

According to FnGuide, consolidated operating losses ran from 2020 to 2023, and in 2023 revenue was KRW 7.4 billion; in 2024 revenue was KRW 10.0 billion with operating profit of KRW 1.1 billion.

On April 2, 2026 the company decided on a third-party rights offering, allotting 1,363,636 new shares at KRW 2,200 each to the 2022 Daishin-SBI KONEX Scale-up Fund. The share price was KRW 2,505 on December 23, 2025. On March 30, 2026 it was KRW 1,850. At 2:20 p.m. on October 26, 2026 it was KRW 669.

As of 17:02 KST on October 27, 2026 the price was KRW 606, down 5.46% from the previous day, with a market capitalization of KRW 9.8 billion and trading value of KRW 94,100. We could not find filings or reports that confirm 2026 interim or quarterly results or the reason for the share price decline.

04

Outlook

The company plans to step up its entry into the US and Indonesia from 2026 to diversify an overseas revenue base centered on China. It plans to devote the KRW 3.0 billion raised in the offering mainly to domestic and overseas marketing.

It has set a transfer to KOSDAQ in 2027 as its goal and says it is accelerating preparations.

On October 26, 2026 the board called an extraordinary shareholders' meeting for December 8, with agenda items to elect a non-executive director and amend the articles to expand the board and create a basis for board committees. The outcome and any governance change should be checked in filings after that meeting.

The business indicators to watch are early sales in the new markets, reliance on Chinese live commerce, and whether the operating margin holds as marketing spending rises. No broker reports or market consensus were found, so no external forecast figures are given.

05

Bull factors

A profit structure turned from loss to profit

According to FnGuide, a company that posted operating losses from 2020 to 2023 earned KRW 1.1 billion in operating profit in 2024. Separate operating profit rose to KRW 2,515 million for fiscal 2025. Reports link the margin improvement to a channel reshuffle that cut home shopping and grew direct online channels. The operating margin may have further room to improve depending on the channel mix.

Export growth and new markets

Export sales rose about 85% to KRW 5.3 billion in 2025. The company said it will step up entry into the US and Indonesia from 2026 to reduce its China concentration. The acquisition of syringe-type gel production equipment responds to higher export demand. A market-research forecast of 20.2% annual growth for global femtech also supports the business backdrop.

Fresh capital and a KOSDAQ transfer drive

In April 2026 the company secured working capital of about KRW 3.0 billion through new shares. The investor is a KONEX scale-up fund co-managed by SBI Investment and Daishin Securities. The company has set a KOSDAQ transfer in 2027 as its target. A transfer could change the trading base, but approval is not assured.

06

Bear factors

Thin trading and large price swings

Trading value on October 27, 2026 was only KRW 94,100. Market capitalization is small at KRW 9.8 billion. The price of KRW 606 is far below the KRW 2,200 issue price of the April 2026 offering. With such thin trading, even small orders can move the price sharply.

A short record of profits

Profits are confirmed for only two years, 2024 and 2025. Operating losses ran from 2020 to 2023, and consolidated equity was negative in 2022. At the end of fiscal 2025, total liabilities of KRW 7,781 million exceeded total equity of KRW 6,502 million. The durability of the earnings improvement is still being tested.

Channel and regional concentration, and pharma uncertainty

The core of 2025 growth was live commerce with Chinese influencers. Revenue that leans on one region or channel can be sensitive to policy or consumer shifts. The pharmaceutical segment is in clinical trials, so commercialization timing and results are undetermined. The new share issue also raised the share count and diluted per-share metrics.

07

Risk factors

Macro

With a large export share, the company can be affected by China's consumer cycle and exchange-rate moves. Changes to live-commerce platform policies or fee structures could alter selling terms. A broad contraction in domestic market activity can weigh more heavily on the liquidity of small KONEX stocks. Specific sensitivities are not confirmed in filings.

Industry and regulatory

Feminine hygiene products are subject to cosmetics regulation and consumer safety standards. Drug development timelines and costs depend heavily on clinical results and approval procedures. As the femtech market grows, competition from domestic and foreign brands may intensify. In new overseas markets, local certification and distribution must come first.

Company-specific

The company was given a pre-notice of designation as an unfaithful disclosure corporation for a delayed disclosure of a tangible asset acquisition decision made in July 2025. It was not designated on December 23, 2025 because of mitigating factors, but the disclosure record remains.

The extraordinary shareholders' meeting on December 8, 2026 will take up a director election and an articles amendment. The 2027 KOSDAQ transfer timeline could change depending on the review outcome.

08

Overall view

Jilgyungyi is a small KONEX femtech company that built a profitable structure in 2024 and 2025 on the back of its feminine hygiene brand. Fiscal 2025 separate revenue of KRW 13,003 million and operating profit of KRW 2,515 million are linked to growth in exports and direct online channels.

On the other hand, its profit record is short, it relies heavily on Chinese live commerce, and its pharmaceutical segment is still in development. The share price is well below the April 2026 offering price and trading value was only KRW 94,100, so price formation is less stable.

Interim and quarterly results for 2026 could not be confirmed, so there is little basis to judge this year's earnings trend. The items to monitor are the outcome of the US and Indonesia entry, the result of the December 8, 2026 extraordinary shareholders' meeting, and preparations for the 2027 KOSDAQ transfer.

09

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 12 more articles and sources
  1. comp.fnguide.com
  2. m.news.nate.com
  3. m.news.nate.com
  4. m.news.nate.com
  5. m.news.nate.com
  6. mt.co.kr
  7. betanews.net
  8. digitaltoday.co.kr
  9. digitaltoday.co.kr
  10. cosmorning.com
  11. m.jilgyungyi.com
  12. giikorea.co.kr

Report written 2026-10-27 · Data as of 2026-10-26

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis